UK-based Pertinax Pharma says that Nigel Brooksby, a former chairman of Sanofi UK, has been appointed as chairman of the company, where he will drive the commercialization of the company’s Pertinax.
His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax, a slow-release technology that provides a continual release of chlorhexidine (CHX).
This unique technology which enablescontrolled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets. Pertinax Pharma – originally a spin out from the University of Bristol – was established in April 2015.
Until his retirement, Mr Brooksby was a member of the Sanofi executive committee in Europe and America and chairman and managing director of the Sanofi Group in the UK and Ireland.
Mr Brooksby is highly regarded as an experienced businessman and entrepreneur in the life sciences arena. Over the last seven years since his retirement from Sanofi, he has been involved as chairman, director and strategic adviser in raising significant investment. In his role as chairman of the UK Life Sciences Strategy Board, he secured a £32 million ($42 million) bid from the UK government for the continued expansion and development of skills for the life sciences sector. In 2015, he was instrumental in gaining a listing for a clinical stage biopharma company on NASDAQ, in which he continues to be a key investor and director. He is also a non-executive director at Porton Biopharma, a director of Stabilitech Pharma, and a non-executive director at Chronos Therapeutics. Mr Brooksby is also chairman of Clinical Insights Ltd and Neurocentrx Pharma.
Mr Brooksby commented: “I am delighted to take on this position at such a pivotal phase in the company’s development. Pertinax has enormous market potential in multiple fields. We are already in talks with several manufacturers and over the course of the next twelve months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”
Michele Barbour, founder and chief scientific officer of Pertinax Pharma, commented: “We are delighted that Nigel has chosen to join our board. His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand. Indeed, we look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as we bring the benefits of our patented and commercialized Pertinax technology to the healthcare sector.”
Source: The Pharma Letter
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).